Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Directorate Change

29 May 2013 07:00

RNS Number : 7347F
Silence Therapeutics PLC
29 May 2013
 



 

Appointment of chief executive and director of corporate development

29th May 2013

Silence Therapeutics plc (AIM: SLN) announces today the appointment of Ali Mortazavi as chief executive and of Annie Cheng as director of corporate development.

Ali Mortazavi joined Silence in August 2012 as director of corporate strategy and since that time has increasingly taken on the mantle of the CEO role. This included overseeing two fundraisings last year to raise £11m for the company and spearheading the £19m placing completed in April 2013. Ali has over 17 years of experience in financial services. He started his career as a Technology Analyst at Duncan Lawrie then Credit Lyonnais Securities. In 2001, he co-founded Evolution Securities and ran the principal trading and market making arm, leaving in 2008. He has extensive experience in small companies and has had significant stakes in UK listed technology / biotech ventures.

Annie Cheng (Annie Jia Huey Cheng), age 37, joins the company after working as a strategy consultant for the Company since October 2012. She has 14 years of experience in the healthcare industry, in equity research and consulting with JP Morgan and boutique investment banks in New York and London.

She has been a director of Visible Value LLP, a biotech consultancy, since December 2011 and of Valor Visible Ltd, its associated business, since October 2012.

There are no other matters to disclose regarding her appointment under Rule 17 or Schedule 2 paragraph (g) of the AIM Rules for Companies.

 

Chairman Jerry Randall said: 'Ali brings a wealth of experience in the capital markets as well as small cap companies, and has been instrumental in the development of Silence since he joined. Annie's combination of investor and commercial experience is very valuable.'

 

Silence Therapeutics

Ali Mortazavi, chief executive/Timothy Freeborn, finance director +44 (0)333 988 0140

a.mortazavi@silence-therapeutics.com

t.freeborn@silence-therapeutics.com

 

N+1 Singer

Shaun Dobson/Jenny Wyllie

+44 20 7496 3000

shaun.dobson@n1singer.com

jenny.wyllie@n1singer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPGUBPAUPWGQR
Date   Source Headline
20th Sep 201712:02 pmRNSPrice Monitoring Extension
13th Sep 201712:07 pmRNSSecond Price Monitoring Extn
13th Sep 201712:02 pmRNSPrice Monitoring Extension
11th Sep 20171:30 pmRNSFurther Strengthens US Patent Estate
8th Sep 201712:07 pmRNSSecond Price Monitoring Extn
8th Sep 201712:02 pmRNSPrice Monitoring Extension
6th Sep 20177:00 amRNSInterim results for six months ended 30 June 2017
4th Sep 20177:00 amRNSNotice of Interim Results
23rd Aug 20177:00 amRNSSave the Date: Capital Markets Event 14 November
17th Aug 20174:05 pmRNSReplacement - Holding(s) in Company
17th Aug 20172:02 pmRNSDirector/PDMR Shareholding
15th Aug 20177:00 amRNSTwo further US patents to be granted
3rd Aug 20177:00 amRNSDirector/PDMR Shareholding
31st Jul 201711:43 amRNSDirector/PDMR Shareholding
31st Jul 20177:00 amRNSHolding(s) in Company
31st Jul 20177:00 amRNSUS patent to be granted
27th Jul 20172:43 pmRNSLicensee Quark Announces Positive AKI Results
24th Jul 20177:00 amRNSPresenting at Canaccord Genuity Growth Conference
24th Jul 20177:00 amRNSSilence Strengthens US Patent Estate
14th Jul 20177:00 amRNSCEO Ali Mortazavi appointed Chairman of Ultromics
10th Jul 20177:41 amRNSIP update
3rd Jul 20172:34 pmRNSIssue of claim in the UK High Courts
3rd Jul 20177:00 amRNSChange of Adviser
29th Jun 201711:47 amRNSHolding(s) in Company
6th Jun 20177:00 amRNSResult of AGM
1st Jun 20177:00 amRNSHiring of Chief Operating Officer
30th May 20177:00 amRNSSilence Continued Expansion of IP
16th May 20177:00 amRNSSignificant Expansion of Intellectual Property
4th May 201712:05 pmRNSNotice of AGM and Publication of Annual Report
3rd May 20177:00 amRNSSilence Therapeutics Presents New Data
12th Apr 20171:30 pmRNSAdditional Listing
3rd Apr 20177:00 amRNSGrant of Share Options to Directors
28th Mar 20177:00 amRNSPreliminary Results for the year to 31 Dec 2016
8th Mar 20177:00 amRNSNotice of Results
13th Jan 20172:03 pmRNSMinority Stake in Arrowhead Pharmaceuticals
9th Jan 20177:00 amRNSAcquisition of Minority Stake in Arrowhead
20th Dec 20167:00 amRNSSilence announces Quark arbitration resolution
15th Nov 20167:00 amRNSCRISPR/Cas9 Gene Editing Data
27th Sep 20167:00 amRNSHalf-year Report
22nd Sep 20167:00 amRNSNotice of Results
5th Sep 20167:00 amRNSAppointment of CSO and Non-Executive Director
18th Jul 20167:00 amRNSDirector/PDMR Shareholding
17th Jun 20163:48 pmRNSResult of AGM
1st Jun 20162:35 pmRNSHolding(s) in Company
24th May 20167:00 amRNSBoard Changes, Advisory Board and Notice of AGM
19th Apr 20167:00 amRNSDirector/PDMR Shareholding
18th Apr 20166:09 pmRNSDirector/PDMR Shareholding
18th Apr 20167:00 amRNSGrant of share options to Chief Executive
5th Apr 20167:00 amRNSAtu027 Update
5th Apr 20167:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.